<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671862</url>
  </required_header>
  <id_info>
    <org_study_id>20190729-01H</org_study_id>
    <nct_id>NCT04671862</nct_id>
  </id_info>
  <brief_title>Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis</brief_title>
  <official_title>Photobiomodulation for the Prevention of Oral Mucositis in Patients Treated With Radiotherapy for Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and&#xD;
      pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try&#xD;
      to reduce the occurence and severity of mucositis in patients treated with radiotherapy for&#xD;
      head and neck cancer&#xD;
&#xD;
      Previous studies in head and neck cancer patients have shown that photobiomodulation (light&#xD;
      therapy) can prevent mucositis. There are currently no centers in Canada using this technique&#xD;
      in routine practice, but this is recommended in International guidelines and widely used in&#xD;
      Europe. The investigators therefore wish to implement this technique in Ottawa under the&#xD;
      umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the&#xD;
      mouth) and pain. Photobiomodulation (Light therapy) will be used before and during&#xD;
      radiotherapy to try to reduce the occurence and severity of mucositis in patients treated&#xD;
      with radiotherapy for head and neck cancer&#xD;
&#xD;
      Rationale: Previous studies in head and neck cancer patients have shown that&#xD;
      photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in&#xD;
      Canada using this technique in routine practice, but this is recommended in International&#xD;
      guidelines and widely used in Europe. The investigators therefore wish to implement this&#xD;
      technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy&#xD;
      in a Canadian context.&#xD;
&#xD;
      Purpose/Objectives: Primary Objective Primary Objective&#xD;
&#xD;
      • To determine the cumulative incidence of acute mucositis as defined by CTCAE version 2.0&#xD;
      for radiation induced mucositis (Appendix 1) during radiotherapy and for 1month following&#xD;
      radiotherapy&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      To determine the following during radiotherapy and for 24 months post-treatment&#xD;
&#xD;
        -  Rate of occurrence of acute radiation dermatitis&#xD;
&#xD;
        -  Pain scores&#xD;
&#xD;
        -  Opioid use&#xD;
&#xD;
        -  ESAS scores during and after RT&#xD;
&#xD;
        -  FACT-HN questionnaire scores&#xD;
&#xD;
        -  Late subcutaneous neck fibrosis&#xD;
&#xD;
        -  Late mucosal and skin telangiectasia&#xD;
&#xD;
      Study design/methodology:&#xD;
&#xD;
      This is single arm prospective cohort study of a single intervention (photobiomodulation) in&#xD;
      patients with head and neck cancer for the prevention of oral mucositis.&#xD;
&#xD;
      Outcomes will be the following:&#xD;
&#xD;
        -  Rates of acute and late mucositis according to CTCAE version 2.0&#xD;
&#xD;
        -  Rates of acute and late dermatitis and fibrosis according to CTCAE version 5.0&#xD;
&#xD;
        -  Rates of late teleangiectasia&#xD;
&#xD;
        -  Pain scores as per Edmonton Symptom assessment scale (ESAS) and modified brief pain&#xD;
           inventory&#xD;
&#xD;
        -  Rates of opioid use&#xD;
&#xD;
        -  FACT-HN scores&#xD;
&#xD;
        -  EQ5D scores&#xD;
&#xD;
      Anticipated public/scientific benefit:&#xD;
&#xD;
      This study aims to study the use of Photobiomodulation treatments for prevention of oral&#xD;
      mucositis. This is recommended in international guidelines but not used in routine practice&#xD;
      in Canada. The benefit of this study is to allow implemetation of this technique in the&#xD;
      Canadian context in a controlled and evaluated manner. This will hopefully then allow further&#xD;
      study and wider implementation of this technique both in Ottawa and in Canada&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of occurence of radiation mucositis</measure>
    <time_frame>7-14 days post radiotherapy</time_frame>
    <description>CTCAE version 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of occurence of radiation mucositis</measure>
    <time_frame>1 month post radiotherapy</time_frame>
    <description>CTCAE version 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of occurence of radiation mucositis</measure>
    <time_frame>3 months post radiotherapy</time_frame>
    <description>CTCAE version 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of occurence of radiation mucositis</measure>
    <time_frame>6 months post radiotherapy</time_frame>
    <description>CTCAE version 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of occurence of radiation mucositis</measure>
    <time_frame>12 months post radiotherapy</time_frame>
    <description>CTCAE version 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of occurence of radiation mucositis</measure>
    <time_frame>24 months post radiotherapy</time_frame>
    <description>CTCAE version 2.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>7-14 days post radiotherapy</time_frame>
    <description>Pain questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>1 month post radiotherapy</time_frame>
    <description>Pain questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>3 months post radiotherapy</time_frame>
    <description>Pain questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>6 months post radiotherapy</time_frame>
    <description>Pain questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>12 months post radiotherapy</time_frame>
    <description>Pain questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>24 months post radiotherapy</time_frame>
    <description>Pain questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Head &amp; Neck (FACT-HN)</measure>
    <time_frame>7-14 days post-radiotherapy</time_frame>
    <description>Swallowing related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Head &amp; Neck (FACT-HN)</measure>
    <time_frame>1 month post-radiotherapy</time_frame>
    <description>Swallowing related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Head &amp; Neck (FACT-HN)</measure>
    <time_frame>3 months post-radiotherapy</time_frame>
    <description>Swallowing related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Head &amp; Neck (FACT-HN)</measure>
    <time_frame>12 months post-radiotherapy</time_frame>
    <description>Swallowing related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Head &amp; Neck (FACT-HN)</measure>
    <time_frame>24 months post-radiotherapy</time_frame>
    <description>Swallowing related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>7-14 days post radiotherapy</time_frame>
    <description>General Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>1 month post radiotherapy</time_frame>
    <description>General Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>3 months post radiotherapy</time_frame>
    <description>General Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>6 months post radiotherapy</time_frame>
    <description>General Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>12 months post radiotherapy</time_frame>
    <description>General Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>24 months post radiotherapy</time_frame>
    <description>General Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>7-14 days post radiotherapy</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>1 month post radiotherapy</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>3 months post radiotherapy</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>6 months post radiotherapy</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>12 months post radiotherapy</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>24 months post radiotherapy</time_frame>
    <description>CTCAE version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Mucositis Oral</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>Photobiomodulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parameters: combined 633nm and 870 nm @1000mW&#xD;
1 Treatment pre radiotherapy&#xD;
3 treatments weekly during radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photobiomodulation</intervention_name>
    <description>Parameters: combined 633nm and 870 nm @1000mW&#xD;
1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)&#xD;
3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)</description>
    <arm_group_label>Photobiomodulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years of age&#xD;
&#xD;
          -  Willing and able to understand and sign informed consent form approved by the&#xD;
             institutional review board (IRB)&#xD;
&#xD;
          -  Histological diagnosis of head and neck cancer of the oral cavity with no evidence of&#xD;
             macroscopic residual disease post-surgery (R0 or R1 resection) and no gross residual&#xD;
             lymphadenopathy in the planned PBM treatment area&#xD;
&#xD;
          -  Planned treatment with radiotherapy or chemoradiotherapy to a dose of ≥ 50 Gy&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Intact oral mucosa (no visible ulceration, dehiscence or active infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gross macroscopic residual disease post surgery (R2 resection) or gross residual&#xD;
             lymphadenopathy in the planned PBM treatment area&#xD;
&#xD;
          -  Prior radiotherapy to the Head and Neck including the oral or oropharyngeal mucosa.&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy in the last 3 months&#xD;
&#xD;
          -  Diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc)&#xD;
&#xD;
          -  Concurrent administration of Cetuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ottawa Health Sciences Research Ethics Board</last_name>
    <phone>613-798-5555</phone>
    <phone_ext>16719</phone_ext>
    <email>REBAdministration@toh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Gaudet, MD MSc MHA</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70206</phone_ext>
      <email>mgaudet@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kristopher Dennis, MD PhD</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70206</phone_ext>
      <email>krdennis@toh.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

